Please login to the form below

Not currently logged in
Email:
Password:

simtuzumab

This page shows the latest simtuzumab news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $201m Dicerna deal

Boehringer bolsters NASH pipeline with $201m Dicerna deal

inhibitor acquired from Nimbus in a $1.2bn deal last year, after its lead inhouse drug simtuzumab failed to show efficacy in trials.

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics